news
FDA approves Carvykti for patients with multiple myeloma
US FDA approval based on 98 percent response rate in multiple myeloma patients treated once with Carvykti (ciltacabtagene autoleucel, cilta-cel).
List view / Grid view
Janssen Research & Development LLC (JRD)
news
Tremfya® ranks highest for skin clearance in psoriatic arthritis patients
Newly published Network Meta-Analysis (NMA) from Janssen indirectly compares all published Phase III data for approved treatments for adults with active Psoriatic Arthritis (PsA).
news
Organ-chips model and predict thrombotic side effect caused by anti-CD154 antibody hu5c8
An Emulate, Inc. study has demonstrated that its Blood Vessel-Chip accurately modelled and predicted thrombosis, or clotting of blood, induced by certain monoclonal antibody drugs, specifically anti-CD154 monoclonal antibody (mAb) hu5c8.
news
Clinical remission data for Stelara in Crohn’s disease presented at DDW
25 May 2016 | By Victoria White, Digital Content Producer
Data shows that a greater proportion of adult patients with Crohn's disease receiving Stelara SC maintenance therapy were in clinical remission at one year...
news
Stelara induces clinical remission in Crohn’s disease in Phase 3 trial
20 October 2015 | By Victoria White
New Phase 3 data show treatment with Janssen’s Stelara (ustekinumab) induced clinical response and clinical remission in patients with moderate to severe Crohn's disease who had previously failed conventional therapy.
news
Johnson & Johnson and collaborators launch the Open Translational Science Project in Schizophrenia
9 June 2015 | By Victoria White
Johnson & Johnson and a group of leading research organisations are launching the OPTICS Project - Open Translational Science in Schizophrenia...
news
U.S. FDA grants Priority Review to simeprevir for combination treatment of genotype 1 chronic hepatitis C
13 May 2013 | By Johnson & Johnson
The U.S. FDA has granted Priority Review to the NDA for simeprevir (TMC435)...
news
New Phase 3 data show STELARA® significantly reduced signs and symptoms of active Psoriatic Arthritis
27 June 2012 | By Janssen Research & Development, LLC
Treatment also resulted in significant improvements in physical function...
news
Janssen Research & Development submits application to U.S. FDA for XARELTO® (rivaroxaban) to reduce secondary cardiovascular events in patients with ACS
29 December 2011 | By Janssen Research & Development, LLC
Janssen Research & Development, LLC (JRD) have announced that it has submitted a sNDA to the FDA seeking approval for the use of XARELTO® (rivaroxaban)...
